0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Acceptance, Awareness, and Knowledge of Human Papillomavirus Vaccine in Eastern Province, Saudi Arabia

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: Human papillomavirus (HPV) is a virus infection and can lead to different epithelial lesions and cancer. Nevertheless, HPV infection is a disease that can be prevented with vaccine. Genital warts, cancer, and HPV infections can all be prevented with this vaccine. In this study, we aimed to investigate awareness, knowledge of HPV infection, and acceptance of its vaccine among the general population in Saudi Arabia.

          Methodology: An observational cross-sectional study was conducted in Eastern Province, Saudi Arabia between September and October 2022, using a self-administered validated questionnaire. beginning with informed consent, followed by questions about demographic data. Finally, there were questions about participants’ knowledge, awareness, and attitudes around HPV and its vaccine.

          Rustles: The results showed 645 participants and only 4% of them had received their HPV vaccination. Knowledge, awareness, and attitude levels were all 35% with mean of 1.14, 28% with mean of 3.03, and 51% with mean of 2.02, respectively. Social media was found to be the most reliable source of information about the HPV vaccine (33%), followed by health practitioners (21%). The most common reasons for refusing vaccinations are “belief we are healthy” (48%), followed by “lack of information” (38%).

          Conclusion: Regarding HPV infection and its vaccination, Saudi Arabia significantly lacks knowledge and awareness. It is essential to provide instructions and information in schools for students, families, and healthcare providers about infection and its vaccination.

          Related collections

          Most cited references14

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

            The Lancet, 374(9686), 301-314
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Human papillomavirus vaccines: WHO position paper, May 2017–Recommendations

              (2017)
              This article presents the World Health Organization's (WHO) recommendations on the use of human papillomavirus (HPV) vaccines excerpted from the WHO position paper on Human papillomavirus vaccines: WHO position paper, May 2017, published in the Weekly Epidemiological Record [1]. This position paper replaces the 2014 WHO position paper on HPV vaccines [2]. The position paper focuses primarily on the prevention of cervical cancer, but also considers the broader spectrum of cancers and other diseases preventable by HPV vaccination. It incorporates recent developments concerning HPV vaccines, including the licensure of a nonavalent (9-valent) vaccine and recent data on vaccine effectiveness, and provides guidance on the choice of vaccine. New recommendations are proposed regarding vaccination strategies targeting girls only or both girls and boys, and vaccination of multiple birth cohorts [3]. Footnotes to this paper provide a number of core references including references to grading tables that assess the quality of the scientific evidence, and to the evidence-to-recommendation table. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines in the global context. Recommendations on the use of HPV vaccines were discussed by SAGE in October 2016; evidence presented at these meetings can be accessed at: www.who.int/immunization/sage/meetings/2016/october/presentations_background_docs/en/.
                Bookmark

                Author and article information

                Journal
                Cureus
                Cureus
                2168-8184
                Cureus
                Cureus (Palo Alto (CA) )
                2168-8184
                22 November 2022
                November 2022
                : 14
                : 11
                : e31809
                Affiliations
                [1 ] Urology, King Faisal University Hospital, Hofuf, SAU
                [2 ] Infectious Disease, King Faisal University, Hofuf, SAU
                Author notes
                Abdullah H. Bohamad abdullah9h9@ 123456gmail.com
                Article
                10.7759/cureus.31809
                9780609
                36579275
                35ddaa39-1f2b-4cc8-b158-b1978cb7e973
                Copyright © 2022, Almaghlouth et al.

                This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 22 November 2022
                Categories
                Urology
                Infectious Disease
                Oncology

                hpv infection,hpv vaccines,malignancy,human papillomavirus (hpv),vaccine,infection

                Comments

                Comment on this article